PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 14C-PF-06826647-LR 600 mg PO
Drug: PF-06826647 600 mg PO
Drug: 14C-PF-06826647 100 ug IV

First Posted Date: 2020-10-19

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT04591262

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands
🇳🇱
PRA Health Sciences Utrecht, Utrecht, Netherlands

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Sasanlimab Prefilled syringe
Drug: Sasanlimab
Drug: Encorafenib
Drug: Axitinib
Drug: SEA-TGT
Drug: Binimetinib

First Posted Date: 2020-10-14

Last Posted Date: 2024-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT04585815

Locations: 🇨🇳
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States

and more 50 locations

Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-06700841 IR
Drug: PF-06700841 MR3
Drug: PF-06700841 MR1
Other: Placebo
Drug: PF-06700841 MR2

First Posted Date: 2020-10-08

Last Posted Date: 2021-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT04580797

Locations: 🇺🇸
Quotient Sciences, Coral Gables, Florida, United States
🇺🇸
Quotient Sciences-Miami, Miami, Florida, United States

A Study to Determine the Bioequivalence of Two Doses of Tafamidis

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tafamidis free acid tablet
Drug: Tafamidis meglumine capsule

First Posted Date: 2020-10-05

Last Posted Date: 2021-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT04575116

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

Phase 3

Completed

Conditions: Acute Migraine

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2020-10-05

Last Posted Date: 2023-12-14

Lead Sponsor: Pfizer

Target Recruit Count: 1648

Registration Number: NCT04574362

Locations: 🇨🇳
1st Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China
🇰🇷
Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of

and more 87 locations

Randomized Trial in Adult Participants With Acute Migraines

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Zavegepant

First Posted Date: 2020-09-30

Last Posted Date: 2023-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 1978

Registration Number: NCT04571060

Locations: 🇺🇸
Meridian Clinical Research, LLC, Savannah, Georgia, United States
🇺🇸
PharmQuest LLC, Greensboro, North Carolina, United States
🇺🇸
Headache Wellness Center, Greensboro, North Carolina, United States

and more 83 locations

Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Conditions: Atopic Dermatitis

First Posted Date: 2020-09-25

Last Posted Date: 2024-10-29

Lead Sponsor: Pfizer

Registration Number: NCT04564755

Locations: 🇺🇸
Beach Allergy and Asthma Specialty Group, A Medical Corporation, Long Beach, California, United States
🇺🇸
Cahaba Dermatology and Skin Health Center, Birmingham, Alabama, United States
🇺🇸
Antelope Valley Clinical Trials, Lancaster, California, United States

and more 52 locations

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Phase 1

Recruiting

Conditions: Liposarcoma
Adenocarcinoma of Lung
Prostate Cancer
Breast Neoplasms

Interventions: Drug: PF-07220060
Combination Product: Letrozole
Combination Product: Enzalutamide
Combination Product: Fulvestrant
Drug: Midazolam

First Posted Date: 2020-09-21

Last Posted Date: 2024-11-18

Lead Sponsor: Pfizer

Target Recruit Count: 337

Registration Number: NCT04557449

Locations: 🇺🇸
Smilow Cancer Center at Yale New Haven-Hospital, New Haven, Connecticut, United States
🇺🇸
Ellison Institute, Los Angeles, California, United States
🇺🇸
Smilow Cancer Hospital at Yale - New Haven, New Haven, Connecticut, United States

and more 42 locations

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: Etrasimod
Drug: Placebo

First Posted Date: 2020-09-21

Last Posted Date: 2024-06-26

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT04556734

Locations: 🇺🇸
UPMC Department of Dermatology, Pittsburgh, Pennsylvania, United States
🇺🇸
UPMC Eye Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Investigate MD, Scottsdale, Arizona, United States

and more 39 locations

Axitinib Therapy Management Study

Withdrawn

Conditions: Renal Cell Carcinoma

First Posted Date: 2020-09-18

Last Posted Date: 2023-11-21

Lead Sponsor: Pfizer

Registration Number: NCT04555603

Locations: 🇺🇸
Pfizer Inc., New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy